Vopratelimab
CAS No. 2039148-04-2
Vopratelimab( —— )
Catalog No. M36893 CAS No. 2039148-04-2
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 692 | Get Quote |
|
| 5MG | 1121 | Get Quote |
|
| 10MG | 1881 | Get Quote |
|
| 25MG | 2732 | Get Quote |
|
| 50MG | 3652 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVopratelimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionVopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS.
-
DescriptionVopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.
-
In Vitro——
-
In VivoAnimal Model:Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model Dosage:0.25-0.3 mg/kg Administration:Intraperitoneal injection; twice a week, for 2 weeks Result:Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2039148-04-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.?
molnova catalog
related products
-
Azetidine-2-carboxyl...
Azetidine-2-carboxylic acid is a non proteinogenic amino acid homologue of proline found in common beets. Azetidine-2-carboxylic acid can be misincorporated into proteins in place of proline in many species including humans. It is a toxic and teratogenic agent.
-
Marmin
Marmin have anti-ulcer effects, which are ascribed primarily to the maintenance of the mucosal barrier integrity and inhibition of gastric motor activity and secondarily due to the prevention of the effects of endogenous acetylcholine and histamine.
-
Sanguinarine
Sanguinarine is a specific inhibitor of Rac1b with anti-microbial, anti-oxidant and anti-inflammatory properties.
Cart
sales@molnova.com